文献速递细胞病理与分子病理神经与头颈病理

ACR TI-RADS 在细胞学不确定甲状腺结节重复穿刺决策中的价值

Utility of ACR TI-RADS to determine need for repeat FNA in thyroid nodules with nondiagnostic cytology.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该回顾性队列研究纳入 139 个首次细胞学为 Bethesda I 类(B1)且经重复活检或手术切除获得明确诊断的甲状腺结节,依据 ACR TI-RADS 评估超声特征并分类。结果显示总体恶性风险为 7.9%,TI-RADS 1–2 类均为 0%、3 类为 2.9%、4 类为 5.9%、5 类为 46.2%,预测恶性的最佳 TI-RADS 分值为 5 分。结论提示 TI-RADS 1–3 类的 B1 结节恶性风险低,可能无需重复活检;TI-RADS 4–5 类者恶性风险较高,应行重复活检。

要点

  • B1 结节总体恶性风险为 7.9%(11/139)。
  • TI-RADS 1–3 类恶性风险低,可能无需重复活检。
  • TI-RADS 4–5 类恶性风险较高,应重复活检。

核心结论

  • TI-RADS 1–3 类的 B1 甲状腺结节恶性风险低,可能无需重复活检。
  • TI-RADS 4–5 类的 B1 结节恶性风险较高,应行重复活检。

研究设计与样本

  • 回顾性队列研究,纳入 139 个首次细胞学为 B1 且经重复活检或手术切除获得明确诊断的甲状腺结节。
  • 评估超声特征并按 ACR TI-RADS 分类,将 TI-RADS 类别与总分同最终诊断比较以确定恶性风险。

主要发现

  • 139 个结节中 11 个(7.9%)为恶性。
  • TI-RADS 1 类和 2 类的恶性风险均为 0%。
  • TI-RADS 3 类的恶性风险为 2.9%。
  • TI-RADS 4 类和 5 类的恶性风险分别为 5.9% 和 46.2%。
  • 预测恶性的最佳 TI-RADS 分值截断值为 5 分。

关键数值与推荐

  • B1 结节总体恶性风险为 7.9%(11/139)。
  • TI-RADS 1–2 类恶性风险均为 0%,3 类为 2.9%,4 类为 5.9%,5 类为 46.2%。
  • 预测恶性的最佳 TI-RADS 分值截断值为 5 分。

临床怎么用

  • 对 B1 结节可结合 ACR TI-RADS 分类评估恶性风险以辅助重复活检决策。
  • TI-RADS 1–3 类的 B1 结节可考虑不重复活检。
  • TI-RADS 4–5 类的 B1 结节应行重复活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nondiagnostic cytology for thyroid nodules, consistent with The Bethesda System for Reporting Thyroid Cytopathology category I (B1) poses a management dilemma for clinicians. The objective of this study was to define the malignancy risk of nodules with B1 cytology using American College of Radiology Thyroid Imaging Reporting & Data System (TI-RADS) and to assess whether TI-RADS can help guide the decision to perform a repeat biopsy of these nodules. MATERIALS AND METHODS: This retrospective cohort study evaluated 139 B1 nodules that had a definitive diagnosis on repeat biopsy or surgical excision. Sonographic features were evaluated and classified according to TI-RADS. TI-RADS category and total points were compared to the final diagnosis to determine the malignancy risk of B1 thyroid nodules. RESULTS: Of the 139 nodules, 11 (7.9%) were malignant. The malignancy risk of nodules assigned TI-RADS category 1 and 2 were both 0%, TI-RADS 3 was 2.9%, whereas TI-RADS 4 and 5 were 5.9% and 46.2%, respectively. The optimal cutoff for TI-RADS points predicting malignancy was 5 points. CONCLUSION: B1 thyroid nodules in TI-RADS categories 1-3 may not require repeat biopsy given low malignancy risk. However, B1 nodules in TI-RADS categories 4 and 5 have a higher malignancy risk and thus should undergo repeat biopsy.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Waters L, Cullen TM, Goldstein MB, et al. Utility of ACR TI-RADS to determine need for repeat FNA in thyroid nodules with nondiagnostic cytology. Cancer Cytopathol. 2026. PMID: 41958111. doi:10.1002/cncy.70093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。